DOCSLIB.ORG

2020-2021 Cancer Communications Committee Disclosures All Relationships Are Considered Compensated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020-2021 Cancer Communications Committee Disclosures All Relationships Are Considered Compensated 2020-2021 Cancer Communications Committee Disclosures All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name EMAIL Committee Employment Leadership Stock and Other Honoraria Consulting or Advisory Speakers' Bureau Research Funding Patents, Royalties, Other Expert Testimony Travel, Other Relationship (OPTIONAL) (OPTIONAL) Open Member Status Ownership Interests Role Intellectual Property Accommodations, Uncompensated Payments Link Expenses Relationships Neeraj Agarwal [email protected] Active Astellas Pharma Active Biotech (Inst) Astellas Pharma Amgen (Inst) AstraZeneca AstraZeneca (Inst) AstraZeneca Bavarian Nordic (Inst) AVEO Bayer (Inst) Bayer BN ImmunoTherapeutics Bristol-Myers Squibb (Inst) Calithera Biosciences Bristol-Myers Squibb (Inst) Eisai Calithera Biosciences EMD Serono (Inst) Exelixis Celldex (Inst) Foundation Medicine Eisai (Inst) Foundation One Inc Exelixis (Inst) Genentech Genentech (Inst) Janssen Oncology GlaxoSmithKline (Inst) Lilly Immunomedics (Inst) Lilly Janssen (Inst) lily Merck (Inst) Medivation/Astellas Newlink Genetics (Inst) MEI Pharma Novartis (Inst) Merck Pfizer (Inst) Nektar Prometheus (Inst) Novartis Rexahn Pharmaceuticals Pfizer (Inst) Pfizer Sanofi (Inst) Pharmacyclics Takeda (Inst) Seattle Genetics TRACON Pharma (Inst) Muhammad S. Beg muhammad.beg@utsouthwestern. Active Array BioPharma Agios (Inst) edu AstraZeneca/MedImmune ArQule (Inst) Cancer Commons AstraZeneca/MedImmune Ipsen (Inst) Legend Biotech Bristol-Myers Squibb (Inst) CASI Pharmaceuticals (Inst) Celgene (Inst) Five Prime Therapeutics (Inst) Genentech (Inst) Immunesensor (Inst) MedImmune (Inst) Merck Serono (Inst) Sillajen (Inst) Tolero Pharmaceuticals (Inst) Suzanne Cole [email protected] Active Exelixis (Inst) Merck Sharp & Dohme (Inst) Robert Dreicer [email protected] Active Astellas Pharma Bristol-Myers Squibb (Inst) Bayer Exelixis (Inst) Eisai Novartis (Inst) EMD Serono Seattle Genetics (Inst) Infinity Merck Myovant Pfizer Pfizer/Astellas Propella Tavanta Veru Cathy Eng [email protected] Active Array BioPharma Bayer Schering Pharma Foundation of Medicine Natera Genetech Sandoz AstraZeneca Julie R. Gralow julie.gralowasco.org Active Immunomedics Melissa M. Hudson [email protected] Active Oncology Research Information Exchange Network Princess Máxima Center Randall J. Kimple [email protected] Active Galera Therapeutics Guidepoint Global #Patent licensed through International Journal of Mele Associates the Univ of North Carolina. Radiation Oncology (I) Biology and Physics #Patent licensed through the Wisconsin Alumni Research Fund (I) #Patent for device to measure tumors Miriam Knoll [email protected] Active AstraZeneca Bristol Myers Squibb Merry Jennifer Markham [email protected] Active GSK Aduro Biotech (Inst) Astra Zeneca (Inst) Lilly (Inst) Novartis (Inst) Tesaro (Inst) VBL Therapeutics (Inst) Jane L. Meisel [email protected] Active Medscape Clovis Oncology Pfizer Pfizer Total Health Eli Lilly Seattle Genetics Puma Biotechnology Conferencing Novartis Total Health Conferencing Pfizer Puma Biotechnology Timothy J. Moynihan [email protected] Active Rita Nanda [email protected] Active Aduro Abbvie (Inst) G1 Therapeutics du Athenex AstraZeneca (Inst) Daiichi Sankyo Celgene (Inst) Genentech/Roche Corcept Therapeutics Immunomedics (Inst) Ionis Genentech/Roche (Inst) Macrogenics Immunomedics (Inst) Merck Merck (Inst) Pfizer Odonate Therapeutics Seattle Genetics (Inst) Pfizer (Inst) Seattle Genetics (Inst) Olatoyosi Odenike [email protected]. Active Abbvie Abbvie (Inst) edu Celgene Agios (Inst) Impact Biomedicines Aprea AB (Inst) Novartis Astex Pharmaceuticals (Inst) AstraZeneca (Inst) Celgene (Inst) CTI BioPharma Corp (Inst) Incyte (Inst) Janssen Oncology (Inst) Kartos (Inst) NS Pharma (Inst) Oncothyrapy (Inst) Nathan A. Pennell [email protected] Active Amgen Altor BioScience (Inst) AstraZeneca AstraZeneca (Inst) Boehringer Ingelheim Bristol-Myers Squibb (Inst) Bristol-Myers Squibb Celgene (Inst) Cota Healthcare Genentech (Inst) G1 Therapeutics Heat Biologics (Inst) Genentech Jounce Therapeutics (Inst) Inivata Loxo (Inst) Janssen Oncology Merck (Inst) Lilly Mirati Therapeutics (Inst) Merck Pfizer (Inst) Mirati Therapeutics Spectrum Pharmaceuticals Pfizer (Inst) Viosera WindMIL (Inst) Xencor Elizabeth R. Plimack [email protected] Active AstraZeneca Astellas Pharma (Inst) # U.S. Patent No.: Bristol-Myers Squibb AstraZeneca (Inst) 14/588,503, Filed Flatiron Bristol-Myers Squibb (Inst) 1/2/2015. (Inst) Genentech/Roche Genentech/Roche (Inst) Infinity Pharmaceuticals Merck Sharp & Dohme Janssen (Inst) MEI Pharma Pfizer (Inst) Merck Pfizer Seattle Genetics Sonali M. Smith [email protected]. Active Abbvie/Genentech Acerta Karyopharm Therapeutics edu Bayer Pharma/AstraZeneca Janssen Oncology Celgene Karyopharm Therapeutics Forty Seven Kite Pharma Novartis Seattle Genetics Pharmacyclics/Janssen TG Therapeutics Portola Pharmaceuticals TG Therapeutics Corey W. Speers [email protected] Active PFS Genomics #Compositions and PFS Genomics Methods for the Analysis of Radiosensitivity, UM- 33550/US-1, Coinventor, Submitted on 09/2013 #Methods and Genomic Classifiers for Prognosis of Breast Cancer and Predicting Benefit from Adjuvant Radiotherapy, Application No. 61/205,279, Co- inventor, Submitted on John W. Sweetenham Robert G. Uzzo [email protected] Active Amgen Janssen Oncology Novartis Genentech/Roche Pfizer UroGen Pharmaceutical.
Load more

Recommended publications
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Markets Center 2010 Endo Pharmaceuticals 1963 Novartis Pharmaceuticals 2019 10-Square Solutions 2019 EMD Serono, Inc. 2019 Novo Nordisk, Inc. 1985 Abbott Laboratories, Inc. 2017 Exelixis 2019 Optinose 2013 AbbVie Inc. 2016 Express Scripts Federal Pharmacy 2018 Organogenesis 2017 ACADIA Pharmaceuticals, Inc. 2010 Federal Practitioner 2004 Otsuka America Pharmaceutical, Inc. 2019 Aimmune 2018 Foundation Medicine, Inc. 2018 Pacira BioSciences, Inc. 2003 Alcon Laboratories, Inc. 2006 Gilead Sciences 2018 Paratek Pharmaceuticals 2017 Alkermes, Inc. 1989 Genentech Inc. 1990 Pfizer Pharmaceuticals 2002 Allergan, Inc. 1983 GLAXOSMITHKLINE 2017 Pharmacyclics, LLC 2019 Almirall LLC 2013 Golden State Medical Supply, Inc. 2019 Portola Pharmaceuticals, Inc. 2019 Alnylam Pharmaceuticals 2019 Greenwich Biosciences 2019 Red One Medical 2019 Altarum Institute 2013 Gulf Coast Pharmaceuticals Plus, LLC 2009 Regenesis Biomedical, Inc. 2012 American Medical Depot 2008 Heritage Health Solutions, Inc. 2019 Relypsa, Inc. 2019 Aptive Resources LLC 2017 Hill-Rom Company 2011 Remund Group, LLC 2013 Arbor Pharmaceuticals, LLC 2018 Hu-Friedy Manufacturing Co 2018 Rigel Pharmaceuticals 2014 Argentum Medical, LLC 2019 Indivior 2016 Sage Products, LLC 2019 ASM Research, LLC 2019 ImmunoVation, LLC 2018 Sage Therapeutics 1986 Astellas Pharma US, Inc. 2019 Incyte Corporation 2000 Sanofi 1995 AstraZeneca 2015 Intercept Pharmaceuticals 2004 Siemens Medical Solutions 2018 Avanir Pharmaceuticals 2019 Ipsen Biopharmaceuticals, Inc. 2019 SK Life Science, Inc. 2017 Bausch Health Companies, Inc. 2018 IT Cadre 2002 Smith & Nephew, Inc. 1985 Baxter Healthcare Corporation 1989 J & J Health Care Systems, Inc. 2019 Sobi Inc. 1996 Bayer Corporation 2014 Jazz Pharmaceuticals Inc.
    [Show full text]
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Spectrum Pharmaceuticals Inc
    SPECTRUM PHARMACEUTICALS INC FORM 10-K (Annual Report) Filed 03/12/14 for the Period Ending 12/31/13 Address 11500 S. EASTERN AVE., SUITE 240 HENDERSON, NV 89052 Telephone 702-835-6300 CIK 0000831547 Symbol SPPI SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2014, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 93 -0979187 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 11500 South Eastern Avenue, Suite 240 Henderson, Nevada 89052 (Address of principal executive offices) (702) 835-6300 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $0.001 par value The NASDAQ Stock Market, LLC Rights to Purchase Series B Junior Participating Preferred Stock Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • Based on Our Discussion with Radford, Management Identified Our Peer Companies to Include the Following 19 Biotechnology and Pharmaceutical Companies for 2015
    Based on our discussion with Radford, management identified our peer companies to include the following 19 biotechnology and pharmaceutical companies for 2015: Ariad Pharmaceuticals Inc. Infinity Pharmaceuticals, Inc. Progenics Pharmaceuticals, Inc. Array BiopPharma, Inc. Lexicon Pharmaceuticals, Inc Repligen Corporation Celldex Therapeutics, Inc. MacroGenics, Inc. Spectrum Pharmaceuticals, Inc. CTI BioPharma Corp. Merrimack Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. DepoMed Inc. NewLink Genetics Corporation XOMA Corporation Halozyme Therpeutics, Inc. OncoMed Pharmaceuticals, Inc. Immunomedics Inc. Peregrine Pharmaceuticals, Inc These peer companies were selected from among publicly-held U.S. pharmaceutical and biotechnology companies with comparable operations in mid– to late–stages of product development or small commercial products in the U.S. based on the following criteria: number and stage of development programs; number of employees; market capitalization; and number of and revenue from commercial products. The market data included information as to base salaries, cash bonuses and stock option awards. Use of Compensation Consultants Our Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities. Our Compensation Committee engaged Radford to analyze historic compensation and establish recommendations for executive compensation for 2015 and methodologies for determining compensation on an on-going basis. Benchmarking in the Context of Our Other Executive Compensation Principles Our Compensation Committee and our Board of Directors use market data as one means of evaluating and establishing executive pay. In instances where an executive officer is believed to be especially suited to our company or important to our success, the Compensation Committee may establish or recommend compensation that deviates from industry averages or other specific benchmarks.
    [Show full text]
  • News Release Tel
    Bayer Pharma AG 13342 Berlin Germany News Release Tel. +49 30 468-1111 Not intended for U.S. and UK Media www.bayerpharma.com Portola Pharmaceuticals Announces Initial Phase II Results Demonstrating Dose-Dependent Reversal of Bayer’s Xarelto® Anticoagulation Activity with Andexanet Alfa (PRT4445) Data set with additional dosing cohorts to be presented at 55th American Society of Hematology (ASH) Annual Meeting and Exposition Berlin, Germany, November 11, 2013 – Bayer HealthCare announced today that initial results from a Phase II proof-of-concept study of Portola Pharmaceuticals’ andexanet alfa, an investigational Factor Xa inhibitor antidote, in healthy volunteers who were administered Bayer’s novel oral anticoagulant Xarelto® (rivaroxaban) have been accepted for presentation at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in New Orleans, LA, USA, from December 7-10, 2013. Initial results from the first two dosing cohorts of the study, submitted by Portola Pharmaceuticals and now published online on the ASH website, demonstrated that andexanet alfa is able to dose-dependently reverse the anticoagulant effects of Xarelto. In addition, no serious adverse events were reported. These data, as well as data from additional cohorts evaluating higher doses of andexanet alfa, will be presented in a poster session on December 9. “Xarelto is a highly effective anticoagulant, and in previous Phase III studies has been shown to significantly reduce the risk of the most concerning bleeding events compared to warfarin. In rare emergency situations when the normalization of blood clotting becomes necessary, stopping Xarelto would allow for normalization of coagulation parameters within one day – this is as effective as giving Vitamin K to patients receiving warfarin,” said Kemal Malik, M.D., Member of the Bayer HealthCare Executive Committee and Head of Global Development.
    [Show full text]
  • JMP Securities Healthcare Conference to Be Held in New York
    JMP Securities Healthcare Conference to Be Held in New York SAN FRANCISCO, Oct 01, 2008 (BUSINESS WIRE) -- JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMPSecurities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008. The two-day conference will feature presentations by senior executives of nearly 90 public and private companies in the biotechnology, medical devices and healthcare services industries before an audience of institutional investors and financial sponsors. For additional details or to register to attend the event, visit www.jmpsecurities.com/about/events.html or www.twstevent.com/jmp.html. Companies scheduled to present as of September 30, 2008; subject to change: A.D.A.M., Inc. ACADIA Pharmaceuticals Inc. Acceleron Pharma, Inc. Achillion Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc. Allos Therapeutics, Inc. Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc. American CareSource Holdings, Inc. Anadys Pharmaceuticals, Inc. ARCA biopharma, Inc. Ardea Biosciences, Inc. athenahealth Inc. AtriCure, Inc. AVEO Pharmaceuticals, Inc. AVI BioPharma, Inc. BioCryst Pharmaceuticals, Inc. C. R. Bard, Inc. Cadence Pharmaceuticals, Inc. Celera Corporation Celgene Corporation Celleration, Inc. Cerus Corporation Chem Rx Corporation Concert Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Cypress Bioscience, Inc. Cytokinetics, Incorporated DexCom, Inc. DiagnoCure Inc. Dialysis Corporation of America Echo Therapeutics, Inc. Eclipsys Corp. Enanta Pharmaceuticals, Inc. Endocare Inc. Exelixis, Inc. EyeGate Pharmaceuticals, Inc. Genomic Health, Inc. Given Imaging, Ltd. HeartWare Limited Horizon Therapeutics, Inc. Human Genome Sciences, Inc. HydroCision, Inc. Idenix Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
    [Show full text]
  • Company Description
    November 8, 2017 Laura S. Engel, CPA [email protected] 214-987-4121 MARKET STATISTICS COMPANY DESCRIPTION Exchange / Symbol NasdaqGS: SPPI Spectrum Pharmaceuticals, Inc. is focused on the acquisition, development and Price: $19.00 commercialization of proprietary drugs, primarily addressing the oncology/hematology Market Cap ($mm): $1,912.6 markets. Spectrum's business strategy involves in-licensing or acquiring diversified drugs Enterprise Value ($mm): $1,766.6 as well as creating an expanding pipeline of prospective candidates in late-stage Phase 2 and Phase 3 clinical trials. Over the years, the Company has developed comprehensive in- Shares Outstanding (mm): 100.7 house clinical development/regulatory capabilities, along with an extensive commercial Float: 85% network, including a direct sales force in the U.S. and distributors in Europe and Japan Volume (3-month avg., mm): 1.8 for its marketed products. Spectrum’s diverse portfolio consists of six marketed oncology drugs and a pipeline with three advanced stage products that address sizable markets. 52-week Range: $3.73 – $21.95 Spectrum Pharmaceuticals is headquartered in Henderson, Nevada, and as last reported, Industry: Biotechnology the Company had 227 employees. CONDENSED BALANCE SHEET ($mm, except per share data) Balance Sheet Date 9/30/2017 SUMMARY Cash & Cash Equivalents: $247.7 Over the last several quarters, Spectrum’s primary focus has shifted beyond its Cash/Share: $2.46 established portfolio of niche cancer drugs to opportunities for its newer drugs, with three in its late-stage pipeline (Poziotinib, Rolontis™, and Qapzola®), and all of which Debt: $101.8 have meaningful competitive advantages and address indications with significant Equity (Book Value): $304.7 populations.
    [Show full text]
  • For Immediate Release
    ______________________________________________________________________________________ FOR IMMEDIATE RELEASE Clinical Trial Application to Conduct Phase III APEX Study of Betrixaban in China was Accepted for Review by China FDA Hong Kong, 28 August 2013 - Lee’s Pharmaceutical Holdings Limited (“the Group”) (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that the Group has successfully submitted an application to the China FDA to expand the Phase 3 APEX ( Acute Medically Ill VTE Prevention with Ex tended Duration Betrixaban) Study of Portola Pharmaceutical’s (Nasdaq: PTLA)_betrixaban into the Chinese population. APEX is an ongoing global randomized Phase 3 clinical study that is evaluating betrixaban, a novel, oral, once-daily Factor Xa inhibitor, for hospital and post-discharge prevention of venous thromboembolism (VTE) in high-risk acute medically ill patients. Currently, there is no anticoagulant approved for extended-duration VTE prophylaxis in this population. Betrixaban directly inhibits the activity of Factor Xa, an important validated target in the blood coagulation pathway. It is specifically designed for chronic, once-a-day treatment, with a half-life that supports true, once-daily dosing and a low peak-to-trough drug concentration ratio that minimizes anticoagulant variability. The clinical study application was submitted with the fast-tract designation, and has been accepted for review by the CFDA (Acceptance Notice Nos. JXHL1300320–40mg & JXHL1300321–80mg). “We’re pleased with the acceptance of review by the CFDA for this important application,” said Dr. Benjamin Li, Chief Executive Officer. “We are looking forward to moving the registration process forward and we’re very anxious for the China trial to get underway in the APEX Study next year.” About Betrixaban and the APEX Study Betrixaban is a novel, oral small molecule that directly inhibits the activity of Factor Xa, an important validated target in the blood coagulation pathway.
    [Show full text]
  • Portola AHA Xa Inhibitor Antidote
    Contacts: Mardi Dier Joey Fleury CFO, Portola Pharmaceuticals Invigorate AHA onsite mobile: 415-509-3632 AHA onsite cell: 925-784-5829 Portola Pharmaceuticals Announces Investigational Universal Factor Xa Inhibitor Antidote Reverses Anticoagulant Activity of Factor Xa Inhibitors – Findings Presented During Oral Presentation at AHA Scientific Sessions – – Elinogrel Data Selected by AHA for “Best of Specialty Conferences” Poster Session – CHICAGO AND SOUTH SAN FRANCISCO, Calif. (November 15, 2010) – Portola Pharmaceuticals, Inc. today announced preclinical study results for PRT064445, its universal Factor Xa inhibitor antidote, demonstrating that the agent can reverse the pharmacodynamic effects of anticoagulation by enoxaparin, a low molecular weight heparin, and fondaparinux, both Factor Xa inhibitors, and reduce blood loss caused by these compounds in an animal model. Previously, Portola presented proof of concept data showing that PRT064445 has the potential to act as a universal antidote to reverse the pharmacodynamic effects of all current and novel Factor Xa inhibitors. The new data were presented today by Portola in the “Novel Concepts for Anticoagulation and Fibrinolysis” oral session from 9 a.m. to noon Central Time during the American Heart Association (AHA) Scientific Sessions 2010 in Chicago. Today, Factor Xa inhibitors are widely used for the treatment and prevention of blood clots. By 2020, they are expected to be used by more than 40 million patients. However, Factor Xa inhibitors can cause clinically relevant bleeding and their anticoagulant activity may need to be reversed in some patients, including those with bleeding-related medical emergencies or those requiring cessation of anticoagulation prior to surgery. No antidote for Factor Xa inhibitors is currently available, and use of procoagulative treatment strategies have potential risks of unwanted thrombosis.
    [Show full text]
  • Portola Pharmaceuticals Announces Data Presentations Highlighting
    Contacts: Mardi Dier Jani Bergan CFO, Portola Pharmaceuticals Invigorate 650-246-7236 415-572-1353 Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif. (December 4, 2010) – Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology’s 52nd Annual Meeting and Exposition. Portola’s novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Poster Presentation Details Specific Inhibition of Syk Suppresses Leukocyte Immune Function and Alleviates Inflammation In Rodent Models of Rheumatoid Arthritis • Presenter: Greg Coffey, Ph.D., Portola Pharmaceuticals • Poster Session: Lymphocytes, Lymphocyte Activation and Immunodeficiency, Including HIV and Other Infections: Poster I • Date: Saturday, December 4, 5:30 - 7:30 p.m. ET • Location: Hall A3/A4 (Orange County Convention Center) • Poster Board I-707 P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity in Primary CLL Cells and is Synergistic with Fludarabine at Low Concentrations • Presenter: Stephen Spurgeon, M.D., Oregon Health & Science University Knight Cancer Institute • Poster Session: Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I • Date: Sunday, December 5, 6:00 - 8:00 p.m. ET • Location: Hall A3/A4 (Orange County Convention Center) • Poster Board II-719 Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia • Presenter: Jan Burger, M.D., Ph.D., MD Anderson Cancer Center • Poster Session: CLL - Biology and Pathophysiology, excluding Therapy: Poster III • Date: Monday, December 6, 6:00 - 8:00 p.m.
    [Show full text]